Loading…
Loading…
AVTR does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for AVTR and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for AVTR and 80,000+ other tickers.
See exactly how AVTR's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for AVTR and 80,000+ other tickers.
Avantor, Inc., a company established in 1904 and based in Radnor, Pennsylvania, is a global provider of vital products and specialized services. Operating across the Americas, Europe, Asia, the Middle East, and Africa, Avantor caters to a wide array of industries, including biopharmaceuticals, healthcare, educational institutions, government bodies, advanced technology firms, and applied materials enterprises. The company's extensive product portfolio features essential materials and consumables, such as high-purity chemicals and reagents, laboratory supplies, custom-formulated silicone…
The market is regaining confidence in Avantor's ability to grow organically and in Emmanuel Ligner's turnaround plan. Biopharma company Regeneron reported a solid set of results, with key drug Dupixent continuing to outpace our and the market's growth expectations. Building products company Fortune Brands Innovations saw its stock price decline in Q3, retracing Q2's positive move related to excitement over Jesse Singh's appointment as CEO.
AVTR's improving commercial execution, specialty product strength and raised 2026 outlook signal recovery potential despite lingering demand challenges.
Shares of Avantor, Inc. (NYSE: AVTR - Get Free Report) have earned a consensus recommendation of "Hold" from the eighteen ratings firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and two have issued a buy rating on the
Investors looking for stocks in the Medical Services sector might want to consider either Viatris (VTRS) or Avantor, Inc. (AVTR). But which of these two stocks is more attractive to value investors?
Avantor, Inc. (NYSE: AVTR - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Tuesday. The stock traded as high as $16.38 and last traded at $15.8730, with a volume of 355253 shares. The stock had previously closed at $15.81. Analyst Ratings Changes Several research firms recently weighed in on AVTR.